US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer therapy more tolerable. The Phase Ib study (NCT06673017) is investigating PTM-101 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback